Taysha Gene Therapies (TSHA) Revenue & Revenue Breakdown
Taysha Gene Therapies Revenue Highlights
Latest Revenue (Y)
$15.45M
Latest Revenue (Q)
$1.79M
Taysha Gene Therapies Revenue by Period
Taysha Gene Therapies Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $15.45M | 517.55% |
2022-12-31 | $2.50M | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Taysha Gene Therapies Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $1.79M | 60.79% |
2024-06-30 | $1.11M | -67.40% |
2024-03-31 | $3.41M | -5.36% |
2023-12-31 | $3.60M | -24.06% |
2023-09-30 | $4.75M | 98.16% |
2023-06-30 | $2.40M | -49.11% |
2023-03-31 | $4.71M | 88.09% |
2022-12-31 | $2.50M | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | - |
Taysha Gene Therapies Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ALEC | Alector | $97.06M | $15.08M |
HOOK | HOOKIPA Pharma | $20.13M | - |
TSHA | Taysha Gene Therapies | $15.45M | $1.79M |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
STTK | Shattuck Labs | $1.66M | $1.61M |
FIXX | Q32 Bio | $1.16M | - |
CCCC | C4 Therapeutics | - | - |
XFOR | X4 Pharmaceuticals | - | $560.00K |
CABA | Cabaletta Bio | - | - |
GOSS | Gossamer Bio | - | $9.48M |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
INZY | Inozyme Pharma | - | - |
BMEA | Biomea Fusion | - | - |
ELYM | Eliem Therapeutics | - | - |
TERN | Terns Pharmaceuticals | - | - |
PRLD | Prelude Therapeutics | - | - |
LRMR | Larimar Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
AKRO | Akero Therapeutics | - | - |